SCHEMBL2860751

SCHEMBL2860751

COc1ccc(Cn2c(=O)c3c(N)n(-c4ccc(Oc5ccccc5)c(OC)c4)nc3c3ccccc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 1/20 0.44
TP53 P04637 2/20 0.41
KMT2A Q03164 2/20 0.41
BLM P54132 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NTRK1 P04629 2/20 0.39
IGF1R P08069 1/20 0.39
FGFR1 P11362 1/20 0.39
NTRK2 Q16620 1/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
RECQL P46063 1/20 0.39
CSF1R P07333 1/20 0.39
GABRA5 P31644 1/20 0.39
TTR P02766 1/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856173 0.90 MEN1 (0.41) TP53KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL2861360 0.88 P2RX4 (0.50) P2RX4TP53KMT2ABLMSMN1; SMN2
SCHEMBL2871092 0.88 P2RX4 (0.54) P2RX4TP53KMT2ABLMSMN1; SMN2
SCHEMBL2865409 0.87 KDM4E (0.41) P2RX4TP53KMT2ABLMSMN1; SMN2
SCHEMBL2862282 0.87 P2RX4 (0.42) P2RX4TP53KMT2ABLMSMN1; SMN2
SCHEMBL2868756 0.85 KMT2A (0.48) P2RX4TP53KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2861755 0.84 P2RX4 (0.48) P2RX4TP53KMT2ABLMSMN1; SMN2
SCHEMBL2868482 0.84 P2RX4 (0.50) P2RX4TP53KMT2ABLMSMN1; SMN2
SCHEMBL2861196 0.83 MAPK1 (0.42) P2RX4TP53KMT2ABLMSMN1; SMN2
SCHEMBL2860000 0.83 MAPT (0.49) P2RX4TP53KMT2ABLMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 P2RX4 718/4885TP53 2049/4885KMT2A 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.